Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arbutus BiopharmaABUS 50 Days Sales Outstanding is 75.64 as of Jun. 2026, which is 42% above its 10-year median of 53.12. GuruFocus rates ABUS with a GF Score™ of 50/100 and a GF Value™ of $49.02 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 841 Biotechnology companies, Arbutus Biopharma ranks better than 98.45% on this metric.
Arbutus Biopharma (NAS:ABUS) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Arbutus Biopharma Days Sales Outstanding Related Terms
Arbutus Biopharma Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Arbutus Biopharma's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABUS vs CADL, WVE, IMMX: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Arbutus Biopharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's Days Sales Outstanding falls into.
Arbutus Biopharma Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma (ABUS) has a Days Sales Outstanding of 75.64 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Arbutus Biopharma and its competitors. This is 42% above median its historical median of 53.12. Over the past decade, Arbutus Biopharma's Days Sales Outstanding has ranged from 2.03 to 156.80. According to the industry distribution chart, Arbutus Biopharma ranks #13 out of 841 companies in the Biotechnology industry, placing it in the top 1.5%.
Is Arbutus Biopharma's Days Sales Outstanding too high?
Arbutus Biopharma's current Days Sales Outstanding of 75.64 is 42% above median its 10-year median of 53.12. Over the past 10 years, this metric has ranged from a low of 2.03 to a high of 156.80. The Biotechnology industry median Days Sales Outstanding is 68.98. Arbutus Biopharma's value of 75.64 is 9.7% above this industry median. Based on the distribution chart, Arbutus Biopharma ranks #13 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arbutus Biopharma has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Days Sales Outstanding compare to CADL and WVE?
According to the Biotechnology industry distribution chart, Arbutus Biopharma ranks #13 out of 841 companies for Days Sales Outstanding. This places Arbutus Biopharma in the top 2% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 68.98. Arbutus Biopharma's value of 75.64 is 9.7% above this benchmark. Historically, Arbutus Biopharma's own Days Sales Outstanding has ranged from 2.03 to 156.80 over the past decade. While the company's 10-year median is 53.12 vs. the industry median of 68.98, Arbutus Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arbutus Biopharma's current Days Sales Outstanding of 75.64 is 9.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Arbutus Biopharma and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arbutus Biopharma's current Days Sales Outstanding is 75.64, which is 42% above median its own 10-year median of 53.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $49.02, compared to a current price of $5.11 — trading 89.6% below its estimated fair value. The current Days Sales Outstanding is 75.64, which is 42% above median its 10-year median of 53.12 and 9.7% above the Biotechnology industry median of 68.98. Arbutus Biopharma's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current Days Sales Outstanding is 75.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arbutus Biopharma (ABUS) Overvalued in 2026?
Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued.
The current stock price of $5.11 is trading 89.6% below its estimated GF Value™ of $49.02.
GuruFocus considers Arbutus Biopharma to be Possible Value Trap.
Key valuation signals for ABUS:
Days Sales Outstanding: 75.64 (42% above median its 10-year median of 53.12)
GF Value™: $49.02 vs. price of $5.11 (89.6% below fair value)
Industry Position: 9.7% above the Biotechnology median (#13 of 841)
No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
50GF Score
Get the complete analysis for ABUS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABUS has been successfully added to your 
